Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial

Study Questions:

What is the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment?